Top Page
Cassava Sciences
(NASDAQ:SAVA)
Cassava Sciences (SAVA) vs. SPDR S&P 500 ETF (SPY)
Cassava Sciences Business Overview & Revenue Model
Cassava Sciences Earnings Call Summary
Cassava Sciences Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -39.51M | 0.00 | -89.42M | -68.03M | 0.00 | -3.05M |
| EBITDA | -65.17M | -141.15M | -104.43M | -78.72M | -32.33M | -6.77M |
| Net Income | -106.03M | -24.34M | -97.22M | -76.25M | -32.38M | -6.33M |
Balance Sheet | ||||||
| Total Assets | 129.73M | 157.53M | 151.66M | 234.83M | 266.78M | 94.30M |
| Cash, Cash Equivalents and Short-Term Investments | 106.08M | 128.57M | 121.14M | 201.01M | 233.44M | 93.51M |
| Total Debt | 0.00 | 0.00 | 0.00 | 139.00K | 236.00K | 293.00K |
| Total Liabilities | 48.16M | 11.83M | 14.20M | 7.29M | 12.87M | 2.10M |
| Stockholders Equity | 81.57M | 145.70M | 137.47M | 227.54M | 253.91M | 92.20M |
Cash Flow | ||||||
| Free Cash Flow | -83.91M | -117.03M | -82.44M | -80.23M | -52.41M | -5.38M |
| Operating Cash Flow | -83.77M | -116.93M | -82.03M | -77.51M | -30.20M | -5.38M |
| Investing Cash Flow | -137.00K | -103.00K | -414.00K | -2.71M | -22.21M | 360.00K |
| Financing Cash Flow | 1.01M | 124.47M | 2.56M | 47.80M | 192.34M | 75.45M |
Cassava Sciences Technical Analysis
Cassava Sciences Risk Analysis
Cassava Sciences Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $307.14M | -2.36 | -172.70% | ― | ― | 5.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $145.47M | 25.00 | 15.95% | ― | 448.44% | ― | |
49 Neutral | $110.48M | -9.56 | -62.16% | ― | ― | 11.78% | |
44 Neutral | $125.35M | -2.91 | -109.73% | ― | ― | 50.39% | |
42 Neutral | $103.86M | -0.97 | -85.44% | ― | ― | -505.96% | |
42 Neutral | $160.78M | -2.37 | -114.26% | ― | -17.87% | 14.42% |
Cassava Sciences Corporate Events
Between August 27 and October 26, 2021, four putative federal securities class actions were filed against Cassava Sciences and certain officers in the U.S. District Court for the Western District of Texas, later consolidated on June 30, 2022 into a single case covering purchasers and sellers of the company’s common stock and options from September 14, 2020 to October 12, 2023. On December 19, 2025, following mediation, Cassava and its CFO Eric J. Schoen agreed via a binding term sheet to pay $31.25 million into escrow, expected in January 2026, to fully settle all claims in the consolidated action in exchange for complete releases for the company and the individually named officers, with the company having already reserved the full settlement amount as a loss contingency in the second quarter of 2025 and seeking court approval for the settlement, which does not constitute an admission of wrongdoing.
The most recent analyst rating on (SAVA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Cassava Sciences stock, see the SAVA Stock Forecast page.
On December 15, 2025, Cassava Sciences received a formal letter from the U.S. Food and Drug Administration placing a full clinical hold on its proposed proof-of-concept trial of simufilam in tuberous sclerosis complex-related epilepsy, pending additional information such as more pre-clinical data and protocol design changes. As a result, the company no longer expects to start the TSC-related epilepsy trial in the first half of 2026, and future timing will depend on how quickly it can satisfy the FDA’s requests and the completion of the agency’s review, potentially slowing its expansion into this indication and affecting development timelines for stakeholders.
The most recent analyst rating on (SAVA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Cassava Sciences stock, see the SAVA Stock Forecast page.
On December 12, 2025, Cassava Sciences‘ Board of Directors approved cash bonus awards for its executives in recognition of their significant contributions in 2025. The company achieved progress on performance measures, including exploring the use of its drug simufilam in Tuberous Sclerosis Complex-related epilepsy, building a specialized team, and managing budgets effectively to support these objectives.
The most recent analyst rating on (SAVA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Cassava Sciences stock, see the SAVA Stock Forecast page.
Cassava Sciences has submitted an IND application to the FDA for a clinical trial of simufilam targeting TSC-related epilepsy. The FDA has requested additional information to assess risks and support the study, and Cassava plans to address these issues and initiate the trial in the first half of 2026.
The most recent analyst rating on (SAVA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Cassava Sciences stock, see the SAVA Stock Forecast page.
On October 23, 2025, the United States District Court for the District of Maryland dismissed the criminal indictment against Dr. Hoau-Yan Wang, a former scientific collaborator with Cassava Sciences. The charges, which included allegations of falsifying research for grant applications, were permanently terminated, allowing Cassava to continue its research efforts without the shadow of legal proceedings, thereby reinforcing its commitment to scientific integrity.
The most recent analyst rating on (SAVA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Cassava Sciences stock, see the SAVA Stock Forecast page.
On October 22, 2025, Cassava Sciences announced the appointment of Dawn C. Bir to its Board of Directors. Ms. Bir, a seasoned biopharmaceutical executive, brings a wealth of experience in leading biotech companies through critical inflection points. Her appointment comes as Cassava prepares to initiate its first clinical study for simufilam in TSC-related epilepsy in the first half of 2026. The company anticipates that her expertise in building shareholder value and forging influential relationships with market stakeholders will be invaluable as they advance their TSC-related epilepsy program.
The most recent analyst rating on (SAVA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Cassava Sciences stock, see the SAVA Stock Forecast page.